TBIO Stock Overview
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Telesis Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.33 |
| 52 Week High | US$3.01 |
| 52 Week Low | US$0.30 |
| Beta | 1.92 |
| 1 Month Change | -38.59% |
| 3 Month Change | 4.32% |
| 1 Year Change | -88.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.21% |
Recent News & Updates
Recent updates
The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More
Apr 17
Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance
Aug 09Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
Jan 06Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021
Sep 24Shareholder Returns
| TBIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -24.1% | -4.9% | -3.7% |
| 1Y | -88.3% | -4.3% | 20.5% |
Return vs Industry: TBIO underperformed the US Life Sciences industry which returned -6.3% over the past year.
Return vs Market: TBIO underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| TBIO volatility | |
|---|---|
| TBIO Average Weekly Movement | 26.1% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TBIO's share price has been volatile over the past 3 months.
Volatility Over Time: TBIO's weekly volatility has increased from 18% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 142 | Todd Nelson | telesisbio.com |
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits which contains the necessary building blocks and reagents, including proprietary gibson assembly branded reagents, for specific synthetic biology workflow applications. It also provides BioXp Select kits which offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications such as cloning, mRNA generation from plasmid and cell free amplification; BioXp Next Generation Sequencing kits which contains the necessary reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents necessary to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom gibson short oligo ligation assembly enzymatic DNA synthesis solutions, designed reduce timelines for constructing synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines.
Telesis Bio, Inc. Fundamentals Summary
| TBIO fundamental statistics | |
|---|---|
| Market cap | US$9.96m |
| Earnings (TTM) | -US$49.02m |
| Revenue (TTM) | US$27.51m |
0.4x
P/S Ratio-0.2x
P/E RatioIs TBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBIO income statement (TTM) | |
|---|---|
| Revenue | US$27.51m |
| Cost of Revenue | US$10.56m |
| Gross Profit | US$16.95m |
| Other Expenses | US$65.97m |
| Earnings | -US$49.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 61.62% |
| Net Profit Margin | -178.21% |
| Debt/Equity Ratio | 17.8% |
How did TBIO perform over the long term?
See historical performance and comparison